Clene (CLNN) Short Interest

View and export this data going back to 2020. Start your Free Trial

What is Clene Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Clene's Short Interest

For the Biotechnology subindustry, Clene's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clene's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clene's Short Interest distribution charts can be found below:

* The bar in red indicates where Clene's Short Interest falls into.

Clene (CLNN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clene Inc (NAS:CLNN) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

84C:Germany

Address

6550 South Millrock Drive, Suite G50, Salt Lake City, UT, USA, 84121

Website

https://www.clene.com

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. Its reportable segments: (1) the development and commercialization of novel clean-surfaced nanotechnology therapeutics (Drugs, and (2) the development and commercialization of dietary supplements (Supplements).

Executives

David J Matlin	director
Matthew Kiernan	director	500 PRINCIPIO PARKWAY WEST, SUITE 400, NORTH EAST MD 21901
Arjun Jj Desai	director	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Robert Dee Etherington	director, officer: Chief Executive Officer	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
John Henry Stevens	director	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Chidozie Ugwumba	director	158 FILMORE STREET, DENVER CO 80206
Alison Mosca	director	26 PATRIOT PLACE, SUITE 301, FOXBORO MA 02035
Jonathon Gay	director	177 HUNTINGTON AVENUE, 21ST FLOOR, BOSTON MA 02115
General Resonance Llc	10 percent owner	6510 SOUTH MILLROCK DRIVE, SUITE 250, HOLLADAY UT 84121
Robert Glanzman	officer: Chief Medical Officer	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Morgan R Brown	officer: Chief Financial Officer	420 CHIPETA WAY, SALT LAKE CITY UT 84108
Vallerie Mclaughlin	director	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Mark Mortenson	officer: Chief Science Officer	500 PRINCIPIO PARKWAY WEST, SUITE 400, NORTH EAST MD 21901
Fiona Costello	director	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Shalom Jacobovitz	director	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121